Consortium for Neuroscience AD/ADRD in Low- and Middle-Income Countries (U01 Clinical Trial Not Allowed)

The NIH's funding opportunity RFA-AG-25-032, "Consortium for Neuroscience AD/ADRD in Low- and Middle-Income Countries (LMICs)," aims to support collaborative research on Alzheimer’s disease (AD) and AD-related dementias (AD/ADRD) in LMICs. This initiative encourages experienced LMIC-based researchers to partner with U.S. scientists to advance research capacity and sustainable infrastructure for dementia-related neuroscience, fostering strategies to prevent and manage AD/ADRD in LMIC contexts. Supported dementia types include frontotemporal dementia, Lewy body dementia, vascular cognitive impairment, and mixed etiology dementias. Structured as a cooperative agreement, this funding opportunity seeks to promote sustainable neuroscience research in LMICs, in alignment with World Bank income classifications for eligible countries. Projects should focus on building local research capacity and long-term research partnerships, contributing to innovative prevention and intervention efforts in these settings. Clinical trials are not permitted under this funding mechanism. The award ceiling is set at $400,000, though the NIH has not specified total program funding or an award floor. Eligible applicants are broad and include public and private higher education institutions, tribal organizations, nonprofits, government entities, small businesses, regional organizations, and non-U.S. entities. Foreign institutions and non-U.S. components of U.S. organizations may apply if they meet eligibility as outlined in the NIH Grants Policy Statement. Applications are due by February 14, 2025, with project funding anticipated to begin later that year. Additional details, including specific project guidelines and application requirements, can be accessed on the NIH grants website.